MX2009010439A - Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. - Google Patents

Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.

Info

Publication number
MX2009010439A
MX2009010439A MX2009010439A MX2009010439A MX2009010439A MX 2009010439 A MX2009010439 A MX 2009010439A MX 2009010439 A MX2009010439 A MX 2009010439A MX 2009010439 A MX2009010439 A MX 2009010439A MX 2009010439 A MX2009010439 A MX 2009010439A
Authority
MX
Mexico
Prior art keywords
breast cancer
diagnosis
risk assessment
chr16
chr2
Prior art date
Application number
MX2009010439A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Sulem
Andrei Manolescu
Simon Stacey
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2009010439A publication Critical patent/MX2009010439A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2009010439A 2007-03-26 2008-03-26 Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. MX2009010439A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8625 2007-03-26
IS8648 2007-05-25
PCT/IS2008/000009 WO2008117314A2 (en) 2007-03-26 2008-03-26 Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Publications (1)

Publication Number Publication Date
MX2009010439A true MX2009010439A (es) 2009-10-20

Family

ID=39563444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010439A MX2009010439A (es) 2007-03-26 2008-03-26 Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.

Country Status (13)

Country Link
US (1) US20110117545A1 (enExample)
EP (3) EP2540840A3 (enExample)
JP (1) JP5676245B2 (enExample)
KR (1) KR20090127939A (enExample)
CN (1) CN101874120B (enExample)
AU (1) AU2008231425B2 (enExample)
CA (1) CA2681928A1 (enExample)
EA (1) EA019953B1 (enExample)
IL (1) IL201217A (enExample)
MX (1) MX2009010439A (enExample)
NZ (1) NZ580490A (enExample)
WO (1) WO2008117314A2 (enExample)
ZA (1) ZA200907471B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827314B2 (en) 2003-12-08 2017-11-28 Mars, Incorporated Edible compositions which are adapted for use by a companion animal
DK2458017T3 (en) 2005-11-29 2017-07-03 Cambridge Entpr Ltd Markers for breast cancer
EP2313525A2 (en) 2008-07-07 2011-04-27 Decode Genetics EHF Genetic variants for breast cancer risk assessment
EP2342353A1 (en) * 2008-10-03 2011-07-13 Mars, Incorporated Genetic test for liver copper accumulation in dogs and low copper pet diet
MX2011012913A (es) * 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
US8356023B2 (en) * 2009-07-28 2013-01-15 Ancestry.Com Operations Inc. Collaborative systems and methods for constructing representations of data
EP2721180A4 (en) * 2011-06-16 2015-09-02 Decode Genetics Ehf GENETIC VARIANTS FOR PREDICTING THE RISK OF BREAST CANCER
GB201120989D0 (en) 2011-12-06 2012-01-18 Mars Inc Genetic test
KR101390590B1 (ko) * 2012-06-28 2014-04-30 서울대학교산학협력단 췌장암 재발 예후 예측용 마커 및 이의 용도
EP2968371A4 (en) 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
KR102334702B1 (ko) 2014-09-30 2021-12-06 지네틱 테크놀로지스 리미티드 유방암 발생 위험의 평가 방법
CN109155149A (zh) * 2016-03-29 2019-01-04 瑞泽恩制药公司 遗传变体-表型分析系统和使用方法
CN108588263B (zh) * 2018-06-07 2022-02-01 中国农业科学院烟草研究所 一种用于定位和克隆植物中控制同一性状的双隐性基因的方法
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
US10395772B1 (en) * 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
WO2020117869A1 (en) 2018-12-03 2020-06-11 Tempus Labs Clinical concept identification, extraction, and prediction system and related methods
KR102091790B1 (ko) * 2019-09-02 2020-03-20 주식회사 클리노믹스 피검사자와 생물체 간의 유전자 정보를 이용한 유전적 띠 제공 시스템 및 그 방법
CA3154157A1 (en) 2019-09-13 2021-03-18 23Andme, Inc. Methods and systems for determining and displaying pedigrees
WO2024096618A1 (ko) * 2022-11-02 2024-05-10 주식회사 디시젠 암 발생 위험도 예측 방법
CN116287258B (zh) * 2023-02-23 2025-08-26 清华大学深圳国际研究生院 一种新型分子标志物在乳腺癌诊断或预后评估中的应用
CN119381001A (zh) * 2025-01-02 2025-01-28 四川大学华西医院 一种乳腺癌复发风险的预测方法、装置、设备及存储介质
CN120805003B (zh) * 2025-09-04 2025-12-02 四川大学华西医院 一种基于多阶段动态优化的时序数据突变检测方法、系统和存储介质

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
EP1423535A4 (en) * 2001-08-04 2005-07-06 Whitehead Biomedical Inst HAPLOTYP CARD OF THE HUMAN GENOME AND USES THEREOF
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US9157122B2 (en) * 2004-11-11 2015-10-13 Garvan Institute Of Medical Research Method of diagnosing cancer and reagents therefor
KR101138862B1 (ko) * 2005-02-14 2012-05-14 삼성전자주식회사 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
KR101206028B1 (ko) * 2005-03-05 2012-11-28 삼성전자주식회사 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이
US7858303B2 (en) * 2005-03-14 2010-12-28 Wisconsin Alumni Research Foundation Method of analyzing breast cancer susceptibility and resistance
WO2006121991A2 (en) * 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer

Also Published As

Publication number Publication date
EA019953B1 (ru) 2014-07-30
EP2540840A3 (en) 2013-05-15
EP2527466A2 (en) 2012-11-28
NZ580490A (en) 2012-08-31
AU2008231425A1 (en) 2008-10-02
CA2681928A1 (en) 2008-10-02
ZA200907471B (en) 2014-03-26
WO2008117314A3 (en) 2008-12-18
EP2137324A2 (en) 2009-12-30
IL201217A0 (en) 2010-05-31
EA200970891A1 (ru) 2010-04-30
KR20090127939A (ko) 2009-12-14
AU2008231425B2 (en) 2014-03-20
CN101874120B (zh) 2015-01-14
EP2527466A3 (en) 2013-05-15
US20110117545A1 (en) 2011-05-19
JP2010522555A (ja) 2010-07-08
JP5676245B2 (ja) 2015-02-25
CN101874120A (zh) 2010-10-27
EP2540840A2 (en) 2013-01-02
WO2008117314A2 (en) 2008-10-02
IL201217A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
MX2009004522A (es) Variantes de suceptibilidad a cancer en chr8q24.21.
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2010004590A3 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
MX2011012913A (es) Métodos para evaluar el riesgo de cáncer de mama.
WO2011073629A3 (en) Cancer diagnosis and treatment
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
MX2012003329A (es) Metodo para identificar si un paciente respondera o no a la inmunoterapia.
WO2009105457A3 (en) Slit2 cancer markers
MY155340A (en) Use of cathepsin c
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2013081645A3 (en) Erbb3 mutations in cancer
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration